<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575259</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-PDD-EP-001</org_study_id>
    <nct_id>NCT04575259</nct_id>
  </id_info>
  <brief_title>OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001</brief_title>
  <official_title>Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anavex Australia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Germany GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety&#xD;
      and efficacy of daily treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety&#xD;
      and efficacy of daily treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>48 weeks</time_frame>
    <description>To continue assessing the safety and tolerability of ANAVEX2-73</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RSBDQ (REM Sleep Behavior Disorder Screening Questionnaire)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to End of Treatment as measured by RSBDQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS Part III Total Score (Motor Scores)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to End of Treatment as measured by MDS-UPDRS Part III Total Score (Motor Scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA (Montreal Cognitive Assessment)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to End of Treatment as measured by MoCA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Microbiota</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to End of Treatment as measured by microbiota</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinson Disease Dementia</condition>
  <arm_group>
    <arm_group_label>ANAVEX2-73 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANAVEX2-73</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>ANAVEX2-73 Active</arm_group_label>
    <other_name>Blarcamesine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous completion of participation in the ANAVEX2-73-PDD-001 study.&#xD;
&#xD;
          -  Caregivers and subjects (or legal representative) must understand and have signed&#xD;
             approved informed consent.&#xD;
&#xD;
          -  Caregivers and subjects (or legal representative) must be able to understand study&#xD;
             requirements and be willing to follow instructions.&#xD;
&#xD;
          -  Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine&#xD;
             agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable&#xD;
             for at least 4 weeks prior to Baseline.&#xD;
&#xD;
          -  Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine&#xD;
             (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable&#xD;
             for a minimum of 8 weeks prior to joining this study.&#xD;
&#xD;
          -  Subjects with history of depression on antidepressant medications will be allowed if&#xD;
             depression is controlled and they have been on a stable daily dose of the&#xD;
             antidepressant for ≥8 weeks before Baseline.&#xD;
&#xD;
          -  Contraception: Women of childbearing potential must use an acceptable method of&#xD;
             contraception starting 4 weeks prior to study drug administration and for a minimum of&#xD;
             4 weeks after study completion. Otherwise, women must be postmenopausal (at least one&#xD;
             year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or&#xD;
             equal to 40 mIU/mL or 40 IU/L or be surgically sterile.&#xD;
&#xD;
          -  Men with a potentially fertile partner must have had a vasectomy or be willing to use&#xD;
             an acceptable method of contraception for the duration of the study and for 3 months&#xD;
             after study drug discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any significant neurologic or psychiatric disorder other than PD that can&#xD;
             contribute to cognitive impairment.&#xD;
&#xD;
          -  Any other condition or clinically significant abnormal findings on the physical or&#xD;
             neurological examination, medical and psychiatric history, at screening or at baseline&#xD;
             that, in the opinion of the Investigator, would make the subject unsuitable for the&#xD;
             study.&#xD;
&#xD;
          -  Potential symptomatic causes of cognitive impairment including but not limited to&#xD;
&#xD;
          -  abnormal thyroid function test at screening (TSH)&#xD;
&#xD;
          -  abnormal B12 level at screening&#xD;
&#xD;
          -  MRI findings (by history) pointing to a potential symptomatic cause of cognitive&#xD;
             dysfunction, including significant vascular changes, or communicating hydrocephalus.&#xD;
&#xD;
          -  Treatment with memantine or amantadine. If appropriate the drugs can be discontinued&#xD;
             for a minimum of 4 weeks prior to enrollment.&#xD;
&#xD;
          -  History of depression as measured by Beck Depression Inventory score &gt;17 at screening.&#xD;
&#xD;
          -  Treatment with any other investigational drug or device within 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Smoking &gt; 1 pack of cigarettes per day (as assessed for the 4 weeks prior to&#xD;
             screening).&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Known allergy or sensitivity to ANAVEX2-73 or any of its components.&#xD;
&#xD;
          -  Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or&#xD;
             type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active&#xD;
             suicidal ideation with some intent to act, without a specific plan. Type 5 indicates&#xD;
             active suicidal ideation with a specific plan and intent.&#xD;
&#xD;
          -  Use of centrally acting anticholinergic drugs during the 4 weeks before enrollment.&#xD;
&#xD;
          -  Medications used for overactive bladder will be allowed provided that the regimen has&#xD;
             been stable 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Treatment with any dopamine receptor blocking medications with the exception of low&#xD;
             dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.&#xD;
&#xD;
          -  History of neurosurgical intervention (e.g., deep brain stimulation) for PD.&#xD;
&#xD;
          -  Unpredictable motor fluctuations that would interfere with administering cognitive&#xD;
             assessments in the ON state.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KaRa MINDS</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalyn Lai, Dr</last_name>
      <phone>+61 2 8960 7788</phone>
      <email>info@karaminds.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammond Care</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Macfarlane, A/Prof</last_name>
      <phone>+61 1300 426 666</phone>
      <email>info@dementiacentre.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua Terrasa</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Pastor</last_name>
      <phone>+34 937 36 70 20</phone>
      <email>contacta@mutuaterrassa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Hernández Vara</last_name>
      <phone>+34 934 89 30 00</phone>
      <email>contacta@vallhebron.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Toribio</last_name>
      <phone>+34 911 91 20 00</phone>
      <email>contacta@comunidad.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Martín Bastida</last_name>
      <phone>+34 913 53 19 20</phone>
      <email>madridcunatpacte@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocío García Ramos</last_name>
      <phone>+34 913 30 30 00</phone>
      <email>neurol.hcsc@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Sánchez</last_name>
      <phone>+34 911 91 60 00</phone>
      <email>atepac.hpth@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias (HUCA)</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Blázquez Estrada</last_name>
      <phone>+34 985 10 80 00</phone>
      <email>contacta@hca.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Mir</last_name>
      <phone>+34 955 01 20 00</phone>
      <email>uec.hvr.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

